Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

NCT06592599 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Toripalimab
RADIATION: Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation

Sponsor

Stanford University